Igor W Blau Selected Research

Therapeutics

10/2021	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
1/2021	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
1/2020	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
5/2019	Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
1/2019	Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.
7/2015	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
3/2013	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
1/2009	Central nervous system infections in immunocompromised patients: update on diagnostics and therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Igor W Blau Research Topics

Disease

11	Multiple Myeloma 10/2021 - 01/2012
3	Infections 01/2020 - 01/2009
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 01/2015
2	Neoplasms (Cancer) 05/2019 - 04/2012
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2016 - 07/2015
2	Leukemia 11/2013 - 04/2010
2	Hematologic Neoplasms (Hematological Malignancy) 04/2012 - 07/2010
1	Bronchiolitis Obliterans Syndrome 01/2021
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2021
1	Inflammation (Inflammations) 01/2020
1	Lymphoma (Lymphomas) 01/2019
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2019
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2012
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 09/2011
1	Acute Megakaryoblastic Leukemia (Leukemia, Megakaryocytic) 07/2011
1	Encephalitis (Encephalitis, Rasmussen) 01/2011
1	Viral Encephalitis 01/2011
1	Progressive Multifocal Leukoencephalopathy 01/2011
1	Pathologic Complete Response 07/2010
1	Disease Progression 04/2010
1	Central Nervous System Infections (Central Nervous System Infection) 01/2009

Drug/Important Bio-Agent (IBA)

9	Bortezomib (Velcade)FDA Link 10/2021 - 01/2012
3	Lenalidomide (CC 5013)FDA Link 01/2021 - 04/2012
3	fludarabineIBA 09/2011 - 01/2009
2	Uric Acid (Urate)IBA 01/2020 - 01/2015
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 07/2015
2	treosulfanIBA 09/2011 - 07/2010
2	Alemtuzumab (Campath)FDA Link 01/2011 - 01/2009
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Melphalan (Alkeran)FDA LinkGeneric 01/2021
1	felzartamabIBA 05/2020
1	Monoclonal AntibodiesIBA 05/2020
1	Ferritins (Ferritin)IBA 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2015
1	Caspase 3 (Caspase-3)IBA 04/2012
1	perifosineIBA 04/2012
1	Trypan Blue FDA Link 04/2012
1	CaspasesIBA 04/2012
1	Annexin A5IBA 04/2012
1	Chemokine ReceptorsIBA 02/2009
1	CD4 Antigens (CD4 Antigen)IBA 02/2009

Therapy/Procedure

9	Stem Cell Transplantation 01/2021 - 04/2010
8	Therapeutics 10/2021 - 01/2009
2	Hematopoietic Stem Cell Transplantation 09/2011 - 07/2010
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2019
1	Retreatment 03/2013
1	Kidney Transplantation 07/2011